Page last updated: 2024-11-02

oxotremorine and Cancer of Parathyroid

oxotremorine has been researched along with Cancer of Parathyroid in 1 studies

Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.

Research Excerpts

ExcerptRelevanceReference
"The effect of the muscarine-like acting parasympathomimetic drug oxotremorine and its antagonist atropine on PTH release was tested using single cell suspensions obtained from a) primary parathyroid adenomas, and b) secondary hyperplastic parathyroid tissue from patients undergoing chronic hemodialysis."3.67The effect of oxotremorine on in-vitro secretion of parathyroid hormone. ( Krause, U; Rothmund, M; Wagner, PK, 1987)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wagner, PK1
Krause, U1
Rothmund, M1

Other Studies

1 other study available for oxotremorine and Cancer of Parathyroid

ArticleYear
The effect of oxotremorine on in-vitro secretion of parathyroid hormone.
    Experimental and clinical endocrinology, 1987, Volume: 90, Issue:3

    Topics: Adenoma; Cells, Cultured; Humans; Hyperplasia; Oxotremorine; Parathyroid Glands; Parathyroid Hormone

1987